Ken Griffin Fsd Pharma Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.77 - $1.81 $15,051 - $35,381	-19,548 Reduced 88.09%	2,643 $4,000
Q4 2022 Feb 14, 2023	BUY	$0.73 - $1.07 $3,119 - $4,572	4,273 Added 23.85%	22,191 $17,000
Q3 2022 Nov 14, 2022	SELL	$0.78 - $1.02 $2,116 - $2,768	-2,714 Reduced 13.15%	17,918 $15,000
Q2 2022 Aug 15, 2022	SELL	$0.78 - $1.1 $52,576 - $74,146	-67,406 Reduced 76.56%	20,632 $16,000
Q2 2021 Aug 16, 2021	BUY	$1.56 - $2.13 $84,644 - $115,571	54,259 Added 160.63%	88,038 $153,000

Q1 2021 May 17, 2021	BUY	$1.65 - $3.87 $5,855 - $13,734	3,549 Added 11.74%	33,779 $65,000
Q4 2020 Feb 16, 2021	BUY	$1.36 - $2.7 $41,112 - $81,621	30,230 New	30,230 $47,000

Ticker HUGE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 38,218,100
Market Cap $5.73M
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.